Description
DAPAZIGA – 10 TAB is a once-daily oral antidiabetic tablet containing Dapagliflozin 10 mg, a selective SGLT2 (sodium-glucose co-transporter-2) inhibitor. It is primarily prescribed for adults with type 2 diabetes mellitus to improve glycemic control, and is also recommended for patients with heart failure or chronic kidney disease (CKD) due to its cardiovascular and renal benefits.
Mechanism of Action:
Dapagliflozin lowers blood sugar by blocking glucose reabsorption in the kidneys and promoting its excretion through urine. It works independently of insulin, making it effective across a range of diabetes progression stages.
Therapeutic Uses:
-
Type 2 Diabetes Mellitus (T2DM) – improves blood sugar control
-
Heart Failure with Reduced Ejection Fraction (HFrEF) – reduces hospitalization risk
-
Chronic Kidney Disease (CKD) – slows progression and reduces risk of renal failure
-
Can be used alone or with other antidiabetic drugs like metformin or insulin
Key Benefits:
-
Lowers HbA1c, fasting, and postprandial blood glucose
-
Promotes weight loss and reduces blood pressure
-
Provides cardiorenal protection in at-risk patients
-
Low risk of hypoglycemia when used as monotherapy
Manufactured under WHO-GMP and ISO-certified facilities, DAPAZIGA – 10 TAB is exported by BLUEPILL EXPRESS, a globally trusted pharmaceutical supplier. BLUEPILL EXPRESS ensures compliance, quality assurance, and timely international delivery to markets across Asia, Africa, the Middle East, Latin America, and Europe.
